Podium to Practice: EHA 2025 – Lymphoma: RESULTS OF 288 PTS TREATED IN OPTIMAL>60 TRIAL OF THE DSHNHL/GL
OR
Explore more from your favourite experts – click their name to access their entire library of content.
Chair
Speakers
Studies / Trials Discussed
S249 – EXCELLENT OUTCOME WITH INTERIM PET ADAPTED TREATMENT REDUCTION IN ELDERLY DLBCL PTS WITH FAVOURABLE PROGNOSIS: RESULTS OF 288 PTS TREATED IN OPTIMAL>60 TRIAL OF THE DSHNHL/GL
This program has been made possible through unrestricted support from Eli Lilly, Merck & Roche.
Studies/trials discussed:
S249 – EXCELLENT OUTCOME WITH INTERIM PET ADAPTED TREATMENT REDUCTION IN ELDERLY DLBCL PTS WITH FAVOURABLE PROGNOSIS: RESULTS OF 288 PTS TREATED IN OPTIMAL>60 TRIAL OF THE DSHNHL/GL
Login to view content
PLease Enter Your Email to view Content
Pre-Video Survey
By continuing to watch the video, you consent to receiving a post-view survey by email.